The combined application of 3-PO and bevacizumab (a monoclonal antibody targeting VEGF) has been confirmed to reduce GBM cell proliferation and increase apoptosis, thereby delaying tumor growth and improving patient survival (81). Here, VEGFA is linked to neoplasm.